Wanbury Limited shares declined 7.6% intraday to ₹314.05 during Tuesday's trading session, according to reports from NDTV Profit. The pharmaceutical company's stock was trading 2.91% lower by 12:10 pm, significantly underperforming the benchmark Nifty 50 index which was down 0.26%. The sharp decline reflects investor concerns over regulatory developments at the company's manufacturing facility. However, recent trading data shows shares recovered to ₹339.85 from the previous close of ₹331.95, with the stock hitting an intraday high of ₹345.00 and low of ₹333.40. The stock saw 22,631 shares traded in over 399 trades with a net turnover of ₹770.25 lakh.
According to the latest reports from Business Standard, the US Food and Drug Administration has concluded its routine current Good Manufacturing Practices (cGMP) inspection at Wanbury's facility in Tanuku, West Godavari District, Andhra Pradesh during the period from July 13 to July 17, 2026. Following the inspection conclusion, the drug regulator issued Form 483 with six observations to the company. The company has officially notified the stock exchange about the US FDA inspection findings and confirmed the completion of the routine cGMP inspection. The filing stated that the company will respond to these observations within the stipulated timeframe as required by the US FDA.
As reported by NDTV Profit, Wanbury has officially notified the stock exchange about the US FDA inspection findings and confirmed the completion of the routine cGMP inspection. The company's filing confirmed that the inspection was routine in nature and that the regulatory authority issued the Form 483 document containing the six observations. The company has committed to responding to these observations within the specified timeframe as required by the US FDA and will keep the stock exchanges informed of any further developments related to the inspection.
Despite the regulatory setback, Wanbury has strengthened its financial position through significant debt management initiatives. On July 15, 2026, the company's Board approved the full early redemption of ₹180 crore in 12.5% Non-Convertible Debentures with outstanding principal. This follows a June 25, 2026 refinancing agreement with Poonawalla Fincorp and Axis Finance, which lowered borrowing costs to sub-10% per annum and released a 40.65% equity share pledge. The company's focus should remain on a robust corrective and preventive action response to avoid long-term impacts on its API export pipeline.
The regulatory developments occur alongside positive international compliance achievements. Wanbury's Tanuku site successfully cleared Australia's Therapeutic Goods Administration inspection in June 2026, validating its core adherence to international pharmaceutical compliance regimes. This follows Korean FDA approval at Patalganga in April 2026, demonstrating the company's globally validated compliance architecture. For a mid-sized pharmaceutical exporter like Wanbury, USFDA audits are a standard operational milestone that occasionally result in observations, with companies generally resolving these within a 15-day window to prevent escalating regulatory actions.
